Quick Comparison

NALTPRL-8-53
Half-Life2-3 hoursEstimated 2-4 hours (limited pharmacokinetic data)
Typical DosageStandard: 300-600 mg NALT 1-2 times daily. Alternatively, plain L-Tyrosine at 500-2000 mg daily (better studied but less water-soluble). Best taken on an empty stomach 30 minutes before a stressful task.Standard: 5-10 mg sublingually 2-3 hours before cognitive demand. Very limited dosing data — the human study used a single 5 mg oral dose. Most users take 5 mg 1-2 times per week. Do not use daily due to lack of chronic safety data.
AdministrationOral (capsules, powder). Take on an empty stomach for best absorption.Oral or sublingual. Sublingual may provide faster onset. Very bitter taste.
Research Papers10 papers1 papers
Categories

Mechanism of Action

NALT

NALT (N-acetyl L-tyrosine) is deacetylated by aryl acylamidase in the gut and liver to release L-Tyrosine. Tyrosine is hydroxylated to L-DOPA by tyrosine hydroxylase (TH) — the rate-limiting step in catecholamine synthesis, requiring tetrahydrobiopterin as cofactor. L-DOPA is decarboxylated by aromatic L-amino acid decarboxylase (AADC) to dopamine; dopamine is converted to norepinephrine by dopamine beta-hydroxylase (DBH), and norepinephrine to epinephrine by phenylethanolamine N-methyltransferase (PNMT). Under stress or sleep deprivation, catecholamine stores in noradrenergic and dopaminergic neurons deplete rapidly. Supplemental tyrosine provides substrate to maintain synthesis when demand exceeds supply, supporting prefrontal cortex function and working memory.

PRL-8-53

PRL-8-53 (methyl 3-(2-(benzhydryloxy)ethyl)aminobutyrate hydrochloride) enhances cholinergic neurotransmission through mechanisms that remain incompletely characterized. It appears to potentiate dopaminergic activity specifically in the basal ganglia (caudate nucleus and putamen) by modulating D2 receptor sensitivity and possibly inhibiting dopamine reuptake via the dopamine transporter (DAT). At higher doses, it exerts inhibitory effects on serotonin signaling, potentially through 5-HT2A receptor antagonism, which may contribute to its memory-enhancing effects by reducing serotonergic interference with dopaminergic memory consolidation pathways. The cholinergic enhancement may involve muscarinic M1 receptor potentiation or acetylcholinesterase modulation. In conditioned avoidance response studies in rats, PRL-8-53 showed potent enhancement of associative learning without affecting spontaneous locomotor activity — suggesting selective cognitive effects without general CNS stimulation or depression. The extraordinary human trial result (87-107% memory improvement in low-performers) suggests a mechanism that specifically amplifies encoding and retrieval processes in the hippocampal-cortical memory circuit.

Risks & Safety

NALT

Common

Mild nausea on empty stomach, headache, heartburn.

Serious

May trigger hypertensive crisis in people taking MAOIs. Avoid with thyroid disorders without medical guidance.

Rare

Insomnia, anxiety, heart palpitations at high doses.

PRL-8-53

Common

Unknown — very limited human data. Single dose in clinical trial was well-tolerated.

Serious

No long-term human safety data exists.

Rare

Unknown.

Full Profiles